Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. 2 billion Pharmaceutical Industrial Park: do the best generic drugs!

Source: CPHI February 2, 2015 recently, Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd plans to invest more than 2 billion yuan in the construction of pharmaceutical industry At present, the company has 3000 square meters of R & D center, nearly 40 million yuan in the past two years, and has purchased 200 advanced experimental instruments and equipment at home and abroad/ Set, for its cardio cerebrovascular, tumor, spirit, anesthesia, urinary, respiratory, antiviral and many other fields of nearly 70 projects In order to meet the growing demand for pharmaceutical orders, Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd has launched the construction of Pharmaceutical Industrial Park since May 2013, with a total planned investment of more than 2 billion yuan, including R & D, production, logistics, logistics, administrative office and supporting life center It is reported that Nanjing Zhengda Tianqing company was founded in 2001 by four shareholders including Thailand Zhengda Group, Jiangsu Agricultural Reclamation group, Zhengda Tianqing Pharmaceutical Group and Nanjing Jinkang At present, it is mainly engaged in drug R & D, production and sales, covering cardio cerebrovascular, tumor, surgery, anesthesia, anti infection, etc Since 2003, the market share of the two generic drugs exceeds that of the original research drugs, the annual compound growth rate of sales of Nanjing Zhengda Tianqing has reached 35% Among them, the billion yuan product group has blossomed "five golden flowers" of tianqingning, yilunping, Getai, Toto and saiweijian, and maintained a high-speed growth Tian Zhoushan, general manager of Nanjing Zhengda Tianqing, said that cardio cerebrovascular and anti-tumor drugs are key areas of research and development Among the 12 high-tech products, cardio cerebrovascular and anti-tumor drugs account for more than half, accounting for the majority of the company's sales At the same time, the company has a number of billion yuan product groups, including tianqingning, yilunping, Getai, Toto, saiweijian and so on The company has a large market for generic drugs In 2014, the above five high-tech products are expected to account for 78% of its annual sales According to IMS data, cardiovascular and cerebrovascular drugs "elanpine" and surgical drugs "Getai" have accounted for 42% and 68% of the market share of similar drugs in China, respectively, surpassing the sales of the original research drugs in China Among them, the annual sales revenue of "yilunping" reached 400 million yuan In addition, the sales volume of its core product "Tuotuo" is expected to reach 300 million yuan this year, with a year-on-year growth of 64% In the near future, the annual design capacity of ordinary freeze-dried powder injection and anti-tumor freeze-dried powder injection will reach 10 million and 5 million respectively after the new factory freeze-dried powder injection workshop which has passed the new GMP certification with Zero Hardware defects is put into operation successfully This will make Zhengda Tianqing one of the top freeze-dried powder injection manufacturers in China High R & D investment to cultivate core competitiveness is an important standard to measure the market position and development potential of pharmaceutical enterprises It is reported that Nanjing Zhengda Tianqing new plant area will build a 35000 square meter research and development center with first-class equipment, with more than 70% of researchers with master's degree or above At present, the company has a research and development center of 3000 square meters, invested nearly 40 million yuan in the past two years, purchased 200 sets of advanced experimental instruments and equipment at home and abroad, and carried out research and development for nearly 70 projects in many fields, such as cardio cerebrovascular, tumor, spirit, anesthesia, urinary tract, respiration, antiviral and so on Focusing on the medium-term goal of "the best generic drugs", Zhengda Tianqing plans to increase its investment year by year The proportion of R & D investment in annual sales revenue will increase from 3% in 2010 to 10% in 2014, and the R & D investment in 2014 will reach 122 million yuan After the new R & D center is put into operation, the R & D investment will be further increased Focusing on the Internet of things, it is reported that Nanjing Zhengda Tianqing new plant area cooperates with China's first-line logistics equipment companies to establish an intelligent storage and logistics distribution center After the completion of the warehouse, the scale will reach 6500 square meters, which is 5 times the storage capacity of the existing traditional warehouse in the way of vertical space storage, realizing a total cargo space of more than 10000 The adoption of advanced logistics automation mechanical equipment and storage system management software aims to build a modern storage logistics center with three-dimensional storage, mechanized operation, intelligent operation and centralized management, which can not only greatly improve efficiency, reduce costs, but also provide strong support for further ensuring drug quality and safety The demand of medicine market changes rapidly, so the overhead warehouse makes the most of the space through three-dimensional storage, improves the land utilization rate, and reduces the land cost At the same time, the design of high turnover, 72 Torr / h (the number of pallet in and out), to achieve multi varieties, multi specifications of raw and auxiliary materials, packaging materials and finished products in and out, speed up the pace of goods access, can meet the actual storage needs